Citations for
1CYLD, DDX58, SDC4
Syndecan-4 negatively regulates antiviral signalling by mediating RIG-I deubiquitination via CYLD.
Lin W, Zhang J, Lin H, Li Z, Sun X, Xin D, Yang M, Sun L, Li L, Wang H, Chen D, Sun Q.
Nat Commun 7:11848. doi: 10.1038/ncomms11848. 2016
2CYLD
CYLD Enhances Severe Listeriosis by Impairing IL-6/STAT3-Dependent Fibrin Production.
Nishanth G, Deckert M, Wex K, Massoumi R, Schweitzer K, Naumann M, Schlüter D.
PLoS Pathog 9(6):e1003455. doi: 10.1371/journal.ppat.1003455. Epub 2013 Jun 27. 2013
3CYLD
Clinical significance of down-regulated cylindromatosis gene (CYLD) in chronic lymphocytic leukemia.
Wu W, Zhu H, Fu Y, Shen W, Xu J, Miao K, Ming H, Xu W, Liu P, Li J.
Leuk Lymphoma euk Lymphoma. 2013 Jun 3. [Epub ahead of print] 2013
4CYLD, PDE4B
Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD.
Komatsu K, Lee JY, Miyata M, Hyang Lim J, Jono H, Koga T, Xu H, Yan C, Kai H, Li JD.
Nat Commun 4:1684. doi: 10.1038/ncomms2674. 2013
5ARHGEF12, CYLD
CYLD regulates RhoA activity by modulating LARG ubiquitination.
Yang Y, Sun L, Tala, Gao J, Li D, Zhou J, Liu M.
PLoS One 8(2):e55833. doi: 10.1371/journal.pone.0055833. Epub 2013 Feb 6. 2013
6CYLD
CYLD, a deubiquitinase specific for lysine63-linked polyubiquitins, accumulates at the postsynaptic density in an activity-dependent manner.
Dosemeci A, Thein S, Yang Y, Reese TS, Tao-Cheng JH.
Biochem Biophys Res Commun 430(1):245-9. doi: 10.1016/j.bbrc.2012.10.131. Epub 2012 Nov 9. 2013
7CYLD
A novel missense mutation of the CYLD gene identified in a Hungarian family with Brooke-Spiegler syndrome.
Nagy N, Farkas K, Kinyo A, Nemeth IB, Kis E, Varga J, Bata-Csorgo Z, Kemeny L, Szell M.
Exp Dermatol 21(12):967-9. doi: 10.1111/exd.12040. 2012
8CYLD
The tumor suppressor CYLD controls the function of murine regulatory T cells.
Reissig S, Hövelmeyer N, Weigmann B, Nikolaev A, Kalt B, Wunderlich TF, Hahn M, Neurath MF, Waisman A.
J Immunol 189(10):4770-6. doi: 10.4049/jimmunol.1201993. Epub 2012 Oct 12. 2012
9CEP192, CYLD
CEP192 interacts physically and functionally with the K63-deubiquitinase CYLD to promote mitotic spindle assembly.
Gomez-Ferreria MA, Bashkurov M, Mullin M, Gingras AC, Pelletier L.
Cell Cycle 11(19):3555-8. doi: 10.4161/cc.21574. Epub 2012 Aug 16. 2012
10CYLD
Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer.
Nikolaou K, Tsagaratou A, Eftychi C, Kollias G, Mosialos G, Talianidis I.
Cancer Cell 21(6):738-50. doi: 10.1016/j.ccr.2012.04.026. 2012
11CYLD
A pro-inflammatory role of deubiquitinating enzyme cylindromatosis (CYLD) in vascular smooth muscle cells.
Liu S, Lv J, Han L, Ichikawa T, Wang W, Li S, Wang XL, Tang D, Cui T.
Biochem Biophys Res Commun 420(1):78-83. doi: 10.1016/j.bbrc.2012.02.118. Epub 2012 Mar 1. 2012
12AKT1, CYLD
CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt.
Lim JH, Jono H, Komatsu K, Woo CH, Lee J, Miyata M, Matsuno T, Xu X, Huang Y, Zhang W, Park SH, Kim YI, Choi YD, Shen H, Heo KS, Xu H, Bourne P, Koga T, Xu H, Yan C, Wang B, Chen LF, Feng XH, Li JD.
Nat Commun 3:771. doi: 10.1038/ncomms1776. 2012
13CYLD, NTRK2, NTRK3
Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.
Rajan N, Elliott R, Clewes O, Mackay A, Reis-Filho JS, Burn J, Langtry J, Sieber-Blum M, Lord CJ, Ashworth A.
Oncogene 30(41):4243-60. doi: 10.1038/onc.2011.133. Epub 2011 May 9. 2011
14CASP8, CYLD
Caspase 8 inhibits programmed necrosis by processing CYLD.
O'Donnell MA, Perez-Jimenez E, Oberst A, Ng A, Massoumi R, Xavier R, Green DR, Ting AT.
Nat Cell Biol 13(12):1437-42. doi: 10.1038/ncb2362. 2011
15CYLD
The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation.
Ahmed N, Zeng M, Sinha I, Polin L, Wei WZ, Rathinam C, Flavell R, Massoumi R, Venuprasad K.
Nat Immunol 12(12):1176-83. doi: 10.1038/ni.2157. 2011
16CYLD
CYLD inhibits tumorigenesis and metastasis by blocking JNK/AP1 signaling at multiple levels.
Miliani de Marval P, Lutfeali S, Jin JY, Leshin B, Selim MA, Zhang JY.
Cancer Prev Res (Phila) 4(6):851-9. doi: 10.1158/1940-6207.CAPR-10-0360. Epub 2011 Apr 8. 2011
17CYLD, HDAC6
CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin.
Wickström SA, Masoumi KC, Khochbin S, Fässler R, Massoumi R.
EMBO J 29(1):131-44. Epub 2009 Nov 5.PMID: 19893491 2010
18CYLD
CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.
Sun SC.
Cell Death Differ 17(1):25-34. Epub . 2010
19CYLD
An inactivating CYLD mutation promotes skin tumor progression by conferring enhanced proliferative, survival and angiogenic properties to epidermal cancer cells.
Alameda JP, Moreno-Maldonado R, Navarro M, Bravo A, Ramírez A, Page A, Jorcano JL, Fernández-Aceñero MJ, Casanova ML.
Oncogene 29(50):6522-32. Epub 2010 Sep 13. 2010
20CYLD
An emerging role of deubiquitinating enzyme cylindromatosis (CYLD) in the tubulointerstitial inflammation of IgA nephropathy.
Cui TG, Ichikawa T, Yang M, Dong X, Li J, Cui T.
Biochem Biophys Res Commun 390(2):307-12. Epub 2009 Oct 1.PMID: 19800320 2009
21CYLD
Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.
Blake PW, Toro JR.
Hum Mutat 30(7):1025-36. Review.PMID: 19462465 2009
22CYLD
Five novel germline function-impairing mutations of CYLD in Italian patients with multiple cylindromas.
Nasti S, Pastorino L, Bruno W, Gargiulo S, Battistuzzi L, Zavattaro E, Leigheb G, De Francesco V, Tulli A, Mari F, Scarrà GB, Ghiorzo P.
Clin Genet 76(5):481-5. Epub 2009 Oct 6. No abstract available. PMID: 19807742 2009
23CYLD, IKBKE
Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation.
Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, Hahn WC, Cantley LC.
Mol Cell 34(4):461-72. 2009
24CYLD
The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration.
Gao J, Huo L, Sun X, Liu M, Li D, Dong JT, Zhou J.
J Biol Chem 283(14):8802-9. Epub 2008 Jan 24. 2008
25CYLD, MFT
CYLD mutations in familial skin appendage tumours.
Saggar S, Chernoff KA, Lodha S, Horev L, Kohl S, Honjo RS, Brandt HR, Hartmann K, Celebi JT.
J Med Genet 45(5):298-302. Epub 2008 Jan 30. 2008
26CYLD, RARRES3
The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response.
Friedman CS, O'Donnell MA, Legarda-Addison D, Ng A, Cárdenas WB, Yount JS, Moran TM, Basler CF, Komuro A, Horvath CM, Xavier R, Ting AT.
EMBO Rep 9(9):930-6. Epub 2008 Jul 18. 2008
27BMF, CYLD, RIPK1
Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway.
Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ, Yuan J.
Cell 135(7):1311-23. 2008
28CYLD
Five new CYLD mutations in skin appendage tumors and evidence that aspartic acid 681 in CYLD is essential for deubiquitinase activity.
Almeida S, Maillard C, Itin P, Hohl D, Huber M.
J Invest Dermatol 128(3):587-93. Epub 2007 Sep 13.PMID: 17851586 2008
29CYLD
The structure of the CYLD USP domain explains its specificity for Lys63-linked polyubiquitin and reveals a B box module.
Komander D, Lord CJ, Scheel H, Swift S, Hofmann K, Ashworth A, Barford D.
Mol Cell 29(4):451-64.PMID: 18313383 2008
30CYLD
The tumor suppressor CYLD regulates entry into mitosis.
Stegmeier F, Sowa ME, Nalepa G, Gygi SP, Harper JW, Elledge SJ.
Proc Natl Acad Sci U S A 104(21):8869-74. Epub 2007 May 10. 2007
31CYLD, WWOX
Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma.
Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D, Chiecchio L, Dachs Cabanas E, Dagrada GP, Nightingale M, Protheroe RK, Stockley D, Else M, Dickens NJ, Cross NC, Davies FE, Morgan GJ.
Blood 110(9):3291-300. Epub 2007 Jul 3.PMID: 17609426 2007
32CYLD
CYLD mutations underlie Brooke-Spiegler, familial cylindromatosis, and multiple familial trichoepithelioma syndromes.
Young AL, Kellermayer R, Szigeti R, Teszas A, Azmi S, Celebi JT.
Clin Genet 70(3):246-9. 2006
33CYLD
TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD.
Stokes A, Wakano C, Koblan-Huberson M, Adra CN, Fleig A, Turner H.
Cell Signal [Epub ahead of print] 2006
34CYLD
Regulation of T cell development by the deubiquitinating enzyme CYLD.
Reiley WW, Zhang M, Jin W, Losiewicz M, Donohue KB, Norbury CC, Sun SC.
Nat Immunol 7(4):411-7. Epub 2006 Feb 26. 2006
35CYLD
CYLD in ubiquitin signaling and tumor pathogenesis.
Ikeda F, Dikic I.
Cell 125(4):643-5. 2006
36CYLD
Adenoviral Vector Expressing CYLD Augments Antitumor activity of TRAIL by Suppression of NF-kappaB Survival Signaling in Hepatocellular Carcinoma.
Chu L, Gu J, He Z, Xiao T, Liu X.
Cancer Biol Ther 5(6) [Epub ahead of print] 2006
37CYLD
A case of Brooke-Spiegler syndrome with a new mutation in the CYLD gene.
Heinritz W, Grunewald S, Strenge S, SchŸtz A, Froster UG, Glander HJ, Paasch U, Simon JC.
Br J Dermatol 154(5):992-4. No abstract available. 2006
38NAO, EDS7C, HSCR5, HYP1, MADYS2, PYCD, PALS, ALPS2, LGMD2A, CASP8D, CYLD
The genetic and molecular bases of monogenic disorders affecting proteolytic systems.
Richard I.
J Med Genet 42(7):529-39. 2005
39BHDS, CYLD, MFT, MFT2, MHAM, MTS, MTS2, NBCCS2
Genetics of skin appendage neoplasms and related syndromes.
Lee DA, Grossman ME, Schneiderman P, Celebi JT.
J Med Genet 42(11):811-9. 2005
40TRAF6, TLR2, CYLD
The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7.
Yoshida H, Jono H, Kai H, Li JD.
J Biol Chem 280(49):41111-21. Epub 2005 Oct 17. 2005
41CYLD, MFT, MFT2
Identification of the cylindromatosis tumor-suppressor gene responsible for multiple familial trichoepithelioma.
Zhang XJ, Liang YH, He PP, Yang S, Wang HY, Chen JJ, Yuan WT, Xu SJ, Cui Y, Huang W.
J Invest Dermatol 122(3):658-64. 2004
42CYLD
Mild phenotype of familial cylindromatosis associated with an R758X nonsense mutation in the CYLD tumour suppressor gene.
Oiso N, Mizuno N, Fukai K, Nakagawa K, Ishii M.
Br J Dermatol 151(5):1084-6. 2004
43CYLD, IKBKB, IKBKG, MAPK8, MAP2K7
Negative regulation of JNK signaling by the tumor suppressor CYLD.
Reiley W, Zhang M, Sun SC.
J Biol Chem 279(53):55161-7. Epub 2004 Oct 20. 2004
44CYLD, IKBKG, NFKB1, TRAF2
The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.
Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G.
Nature 424(6950):801-5. 2003
45CYLD, EDA2R, IKBKG, NFKB1, TRAF2
CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members.
Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G.
Nature 424(6950):793-6. 2003
46CYLD
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB.
Brummelkamp TR, Nijman SM, Dirac AM, Bernards R.
Nature 424(6950):797-801. 2003
47CYLD
A novel missense mutation in CYLD in a family with Brooke-Spiegler syndrome.
Hu G, Onder M, Gill M, Aksakal B, Oztas M, Gurer MA, Celebi JT.
J Invest Dermatol 121(4):732-4. 2003
48CYLD, TRAIP
The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappaB activation by tumor necrosis factor.
Regamey A, Hohl D, Liu JW, Roger T, Kogerman P, Toftgard R, Huber M.
J Exp Med 198(12):1959-64. 2003
49CYLD
Linkage and LOH studies in 19 cylindromatosis families show no evidence of genetic heterogeneity and refine the CYLD locus on chromosome 16q12-q13.
Takahashi M, Rapley E, Biggs PJ, Lakhani SR, Cooke D, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Vloten WA, Breuning MH, van de Ouweland A, Halley D, Delpech B, Cleveland M, Leigh I, Chapman P, Burn J, Hohl D, Gšršg JP, Seal S, Mangion J, Warren W, Bignell G, Stratton Mr.
Hum Genet 106:58-65 2000
50CYLD
Identification of the familial cylindromatosis tumour-suppressor gene.
Bignell GR, Warren W, Seal S, Takahashi M, Rapley E, Barfoot R, Green H, Brown C, Biggs PJ, Lakhani SR, Jones C, Hansen J, Blair E, Hofmann B, Siebert R, Turner G, Evans DG, Schrander-Stumpel C, Beemer FA, van Den Ouweland A, Halley D, Delpech B, Cleveland MG, Leigh I, Leisti J, Rasmussen S.
Nat Genet 25(2):160-5. 2000
51CYLD
A new hereditary cylindromatosis family associated with CYLD1 on chromosome 16.
Thomson SA, et al.
Hum Genet 105(1-2):171-3. 1999
52CYLD
Familial cylindromatosis mimicking tuberous sclerosis complex and confirmation of the cylindromatosis locus, CYLD1, in a large family.
Verhoef S, et al.
J Med Genet 35 : 841-845. 1998
53CYLD, TSG16F
The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cyclindromas.
Biggs PJ, et al.
Oncogene 12 : 1375-1377. 1996
54TSG16F, CYLD
Familial cylindromatosis (turban tumour syndrome) gene localised to chromosome 16q12-q13 : evidence for its role as a tumour suppressor gene.
Biggs PJ, et al.
Nat Genet 11 : 441-443. 1995